上海盟科药业股份有限公司 2025年年度业绩预告

Group 1 - The company expects to achieve an operating revenue of approximately 135 million to 155 million yuan for the year 2025, representing an increase of 4.73 million to 24.73 million yuan compared to the previous year, with a year-on-year growth of 3.63% to 18.98% [1] - The projected net profit attributable to the parent company for 2025 is expected to be between -265 million to -225 million yuan, which is a reduction in losses by 175.72 million to 215.72 million yuan compared to the previous year, indicating a year-on-year decrease in losses of 39.87% to 48.95% [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -274 million to -234 million yuan, reflecting a reduction in losses by 185.17 million to 225.17 million yuan compared to the previous year, with a year-on-year decrease in losses of 40.33% to 49.04% [2] Group 2 - The previous year's operating revenue was 130.27 million yuan [4] - The total profit for the previous year was -434.51 million yuan, with a net profit attributable to shareholders of -440.72 million yuan, and a net profit of -459.17 million yuan after excluding non-recurring gains and losses [5] - The earnings per share for the previous year was -0.67 yuan [6] Group 3 - The increase in operating revenue is attributed to the company's efforts in controlling sales, research and development, and management expenses, optimizing organizational structure, and improving resource utilization efficiency, leading to a decrease in overall costs and expenses compared to the previous year [7]